Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Phillip Garfin
Seagen Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
- University of Southern California
Los Angeles, California, United States
- Rocky Mountain Cancer Centers, Llp
Aurora, Colorado, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- University of Colorado Hospital
Denver, Colorado, United States
- Cancer Specialisits of North Florida
Fleming Island, Florida, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Georgia Regents University Hospital
Augusta, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- University of Minnesota Medical Center (ummc)
Minneapolis, Minnesota, United States
- Bozeman Deaconess Health Group
Bozeman, Montana, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- the University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, United States
- Weill Cornell
Brooklyn, New York, United States
- Westchester Medical Center
Hawthorne, New York, United States
- Columbia University Medical Center
New York, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
- Case Western Reserve University (cwru) - University Hospitals Case Medical Center
Cleveland, Ohio, United States
- Ohio State University
Columbus, Ohio, United States
- Oregon Health & Science
Portland, Oregon, United States
- Providence Portland Research Center
Portland, Oregon, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Medical University of South Carolina
Charleston, South Carolina, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Texas Oncology - Austin Midtown
Austin, Texas, United States
- Baylor University Medical Center
Dallas, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Cancer Care Centers of South Texas
San Antonio, Texas, United States
- Swedish Medical Center
Seattle, Washington, United States
- Froedtert & Medical College of Wisconson Clinical Cancer Center
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2016
- Primary completion
- 6 Nov 2017
- Completion
- 6 Nov 2017
- Last update posted
- 12 Feb 2019
- Registered enrollment
- 19
- Registry id
- NCT02706899
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.